Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
March 31, 2008
Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com
In many respects, it is good that this trial was done. For many years, retinal physicians had used Avastin injections preferentially over Lucentis for the treatment of AMD because of the vast difference in cost.
March 31, 2008
New Focus of Inquiry Into Bribes: Doctors | www.nytimes.com
It is a common business practice for companies to wine and dine potential clients in an effort to secure new business contracts. This is not considered to be a bribe, it is considered good business practice. Is Stryker's case that different? Physicians go into practice for many reasons. Some are altruistic and well meaning, such as a desire to help mankind and heal the sick. Others are pragmatic, such as to put children through college and make a living. Why is it that we are pushed to stress only the altruistic ones and derided for the pragmatic ones? Do you honestly think that Christopher Christy, Jr. is pursuing this case simply for the public good? Or could there perhaps be a pragmatic reason as well, that if he can settle his case for millions of dollars he will be filthy rich. . . . I wonder. . . .
Page : 11 to 2 of 2
February 7, 2012
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
Medtech M&A activity accelerates in 2011
November 30, 2011